HHS Issues Formal RFI for Drug Pricing Blueprint

On May 14, the Department of Health and Human Services (HHS) issued a formal request for information (RFI) regarding the Trump Administration’s proposed drug pricing blueprint. HHS seeks “all suggestions to improve the affordability and accessibility of prescription drugs, including reflections and answers to questions not specifically asked.” Questions specifically posed by HHS are:

• What other regulations or government policies may be increasing list prices, net prices, and out-of-pocket drug spending?
• What other policies or legislative proposals should HHS consider to lower drug prices while encouraging innovation?
• What data or evidence should HHS consider when developing proposals to lower drug prices?
• HHS is actively working to reduce regulatory burdens. To what extent do current regulations or government policies related to prescription drug pricing impose burden on providers, payers, or others?
• To what extent do the planned actions described in this document impose burden, and do these burdens outweigh the benefits?

ACCC will be submitting comments, but we also encourage our member programs to weigh in on this important document. Comments must be submitted on or before July 15, 2018. To submit electronically, go to http://www.regulations.gov.

Posted 5/14/2018